OS Therapies, a clinical-stage biopharmaceutical company, has provided a regulatory update regarding its lead product candidate, as of June 30, 2026. The company is focused on developing treatments for osteosarcoma and other cancers.
According to the update, OS Therapies is progressing with its U.S. regulatory strategy. The company has been in communication with the U.S. Food and Drug Administration (FDA) regarding its development plans. Specific details about the regulatory milestone or submission were not disclosed in the available information.
The company's lead candidate is designed to address unmet medical needs in osteosarcoma, a rare bone cancer. OS Therapies continues to advance its clinical programs and regulatory interactions.
